INTRODUCTION
Hepatocellular carcinoma (HCC) is a major malignancy worldwide and is particularly prevalent in Asia and Africa, being one of the most common causes of mortality (1) . Risk factors for HCC, including infection with hepatitis B or C virus and exposure to aflatoxin B1, have been well documented (1) . However, the molecular events leading to the development and progression of HCC remain elusive.
Clonal expansion of genetically modified cells with inactivated tumor suppressor genes is a hallmark of cancer (2) . One major challenge in HCC research is the identification and characterization of tumor suppressors whose inactivation alters major cellular signaling pathways. The delineation of the mechanisms for hepatocarcinogenesis is of importance as it provides novel opportunities for diagnosis, prognosis and therapeutic interventions.
The dysregulation of p53, Rb, c-myc and Wnt signaling through epigenetic changes and somatic mutations has been implicated in some cases of HCC (3) (4) (5) (6) (7) (8) (9) . However, a number of independent studies based on comparative genomic hybridization, spectral karyotyping, and microsatellite analyses for loss of heterozygosity (LOH) have provided strong evidence for the inactivation of additional tumor suppressors in HCC (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . In particular, deletions on chromosome 13q have been found to be rather common (9, (12) (13) (14) (15) (16) (17) (18) , but a definite gene target in this region has not been identified.
functions implicate Rho proteins as key regulators in oncogenic transformation mediated
by Ras and other oncoproteins (21, 22) . In addition, Rho proteins also stimulate tumor cell invasion and metastasis (20) . Balancing the oncogenic potential of Rho proteins are Rho GTPase-activating proteins (GAPs) that activate the intrinsic GTPase activity of Rho proteins and switch them off by converting the active GTP-bound state to the inactive GDP-bound state. Notably, a candidate tumor suppressor gene at chromosome 8p22-p21. 3 , which has been shown to be frequently deleted in HCC tissue samples and cell lines (23, 24) , contains a putative RhoGAP domain. The re-introduction of this gene termed DLC1 (deleted in liver cancer 1) exerts inhibitory effects on the proliferation of DLC1-defective hepatoma cell lines (24) . However, it is not understood whether DLC1 has RhoGAP activity. Nor is it clear exactly how DLC1 suppresses cell growth and proliferation.
In search for candidate tumor suppressor loci on chromosome 13q, here we identified a novel gene DLC2 at 13q12.3. DLC2 is apparently a DLC1 homolog. Interestingly, DLC2 is underexpressed in HCC tissues. We provided the first evidence that DLC2 has GAP activity specific for RhoA and Cdc42. We demonstrated that the GAP domain of DLC2 inhibits the Rho-mediated assembly of actin stress fibers in cultured cells. In addition to the RhoGAP domain, DLC2 also contains a SAM domain related to p73/p63, and a lipidbinding START domain. Finally, we showed that DLC2 counteracts Ras signaling and All specimens were obtained immediately after surgical resection, snap-frozen in liquid nitrogen, and kept at -70°C. Frozen sections were cut from the tumor and nontumorous liver blocks separately and stained for histological examination to ensure homogeneous cell populations of tissues.
Cloning of DLC2 gene. DLC2 is a previously unidentified gene located at human chromosome 13q12.3. The full length DLC2 cDNA was assembled from EST clones using the DLC2 genomic sequence (Genbank Z92540, AL139187 and Z84483) as a reference. 6 to the full-length sequence of DLC2, thereby dominantly inactivating the GAP activity. All constructs were confirmed by DNA sequencing.
Northern blot analysis. Multiple tissues Northern blot was purchased from Clontech (Palo Alto, CA). The hybridization was performed according to the manufacturer's protocol. A PCR fragment amplified with primers 5'-CTTTCTATTGAAAGCCTCTCT CC-3' (forward) and 5'-ATCCCTCCTGTCTCTGACC-3' (reverse) was used as probe.
LOH studies with 13q markers. Two polymorphic microsatellite markers, D13S171 and D13S267, which flank the DLC2 locus on both sides and are located at 13q12.3-13q13, were used for LOH analyses. PCR using these two microsatellite markers was performed on the DNA extracted from the fresh frozen blocks of HCCs and the corresponding non-tumorous livers, as previously described (25) . PCR products were then analyzed on a model 377 automatic DNA sequencer (Applied Biosystems, Foster city, CA) according to the manufacturer's instructions and the results were analyzed with Genotyper software (Applied Biosystems). Cases were defined as LOH when an allele peak signal from tumor DNA was reduced by 50% compared with their corresponding non-tumorous liver, as we described previously (25) .
RT-PCR.
Total RNA was extracted from HCC and their corresponding non-tumorous livers from with TRIZOL reagent as described by manufacturer (Life Technologies, Gaithersburg, MD). cDNA was synthesized from 1 µg total RNA by using oligo(dT) 16 as primer and with GeneAmp RNA PCR Kit (Applied Biosystems, Foster City, CA). PCR amplification using a set of primers (forward: 5'-AGC CCC TGC CTC AAA GTA TT-3', reverse: 5'-ATG GGC GTC ATC TGA TTC TC-3') was performed to give a product of 403 bp (from nucleotide 2021 to nucleotide 2423), which covered most of the GAP domain of DLC2. A fragment of β-actin was amplified as control. The PCR reaction was performed in Perkin-Elmer's 9700 thermocycler. The PCR was stopped at the exponential 7 phases, 30 cycles for DLC2 and 22 cycles for β-actin, with one cycle of hot-start at 95°C for 12 minutes, followed by amplification at 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 45 seconds, and a final elongation at 72°C for 10 minutes. The PCR products were analyzed by electrophoresis on 1.5% agarose gels and their signal intensities were measured by GelWorks 1D Intermediate Software (UVP). Significant underexpression was defined when the ratio of DLC2 mRNA of the tumor to that of the corresponding nontumorous liver was <0.5 after normalization with β-actin.
Phylogenetic analysis. Phylogenetic analysis of DLC2-related proteins was performed using the PHYLIP software package version 3.6 (http://evolution.genetics.
washington.edu/) as previously described (26, 27) .
Focus formation assay. Focus formation assay was carried out as described (28, 29) .
Briefly, NIH3T3 cells were co-transfected with DLC2-GAP or DLC2-GAP-R699A plasmid (900 ng) plus pUSE-RasV12 construct (Upstate Biotechnology) (100 ng) or plus pRSVvJun (100ng) using the Lipofectamine 2000 reagent (Life Technologies). Plasmid pRSVvJun has been described elsewhere (30, 31) . Cells were selected in medium containing 800 µg/ml G418 after 24 hours and number of foci was scored after 14-21 days.
GTPase activity assay. GTPase activity was assayed as described (32) . Briefly, GSTfusion form of Rac1, Cdc42, and RhoA proteins were purified and digested with thrombin to release the small G-proteins. Purified GST-free small G-proteins (1 µM) were preloaded (33), was used as a positive control in the assay. Expression plasmid for n-chimerin has been described (33).
Protein purification. GST fusion protein was purified as described previously (29, 34) . The protein was eluted with 10 mM reduced glutathione and dialyzed in low salt buffer (10 mM Tris pH 7.6, 2 mM MgCl 2 and 0.1 mM DTT) overnight. Thrombin digestion was performed to cleave the fusion proteins. The excess thrombin was removed by p-aminobenzamidine-Sepharose (Amersham Biosciences) and the quality of the GSTfree proteins was verified on SDS-PAGE gels stained with Coomassie blue. All purified proteins are of over 85% homogeneity.
Luciferase assay. Luciferase activity recovered from extracts of transiently transfected NIH3T3 cells was assayed as previously described (34) . The reporter plasmid pSRE-luc was from Stratagene (La Jolla, CA). This plasmid contains five copies of the SRE element (AGGATGT CCATATTAGG ACATCT) in the promoter that drives the expression of firefly luciferase.
Immunofluorescence microscopy. Laser-scanning confocal microscopy was performed on a Zeiss Axiophot microscope as previously described (29, 34) . Dual immunofluorescent detection was achieved with primary antibodies from two species coupled to pre-absorbed species-specific secondary antibodies. The primary antibodies are a mouse monoclonal antibody against α-actin (ZSA1 from Zymax) and rabbit polyclonal antibodies against HA (Y-11 from Santa-Cruz). The secondary antibodies are Cy5-conjugated goat anti-mouse immnuglobulin G (Zymax) and fluorescein-conjugated goat anti-rabbit immunoglobulin G (Zymax). Plasmid pHM6 (Roche) was used for expression of DLC2-GAP in HeLa cells.
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RESULTS
Identification of human DLC2. LOH studies from many independent groups have strongly suggested the existence of HCC-associated tumor suppressor loci on chromosome 13q (9, (12) (13) (14) (15) (16) (17) (18) . In particular, a small commonly deleted region harboring tumor suppressor(s) has been mapped to 13q12.3 in close proximity to the BRCA2 locus, and a microsatellite marker D13S171 telomeric to BRCA2 has been widely used in the definition of this small region (13) (14) (15) . To search for candidate tumor suppressor in this region, we identified a novel gene designated DLC2 (deleted in liver cancer 2) due to striking homologies to DLC1 at 8p22-p21.3, a frequently deleted locus in HCC (23, 24) .
Thus, DLC2 was chosen to be further characterized because it localizes to a small region of 13q12.3 commonly deleted in HCC, it is homologous to DLC1, and it encodes a putative RhoGAP protein which down-regulates Rho family GTPases.
The physical mapping of DLC2 in human genome has been determined (http://www. To assess the expression patterns of DLC2 in human tissues, we performed Northern blot analysis using an internal fragment of the DLC2 cDNA as probe (Fig. 1C) mRNA when compared with the corresponding non-tumorous liver tissues from the same patients (Fig. 2B) . Thus, DLC2 is commonly underexpressed in HCC.
DLC2 is a multifunctional protein with RhoGAP activity. DLC2 contains multiple domains highly relevant to its putative tumor suppressor function (Fig. 3A) . At the amino acid sequence level DLC2 shares 51% identity and 65% similarity with DLC1. One of most conserved regions between DLC1 and DLC2 locates in the RhoGAP domain (residues 677-826) where 80% residues are identical (Fig. 3B) . Plausibly, this degree of conservation suggests that DLC1 and DLC2 may serve related functions in tumor suppression. A phylogenetic analysis of DLC2-related sequences (Fig. 3C ) lends further support to the notion that DLC1 and DLC2 represent a separate and evolutionarily conserved group of GAP proteins distinct from other GAP proteins such as Macgap or nchimerin.
Four domains or motifs can be identified in the DLC2 sequence (Fig. 3A) . First, DLC2 conserves a RhoGAP domain (35) closely related to that of DLC1 and of other proteins (Fig. 3B) . Thus DLC2 is predicted to show GAP activity on Rho family small To establish the RhoGAP activity of DLC2, we performed in vitro GAP assays using recombinant proteins. A full-length DLC2 protein was bacterially expressed as GST fusion and affinity-purified through glutathione-agarose (Fig. 4A, lane 2) . Purified GST and DLC2 proteins were tested for GAP activity on GST-free RhoA (Fig. 4B) , Rac1 ( Fig.   4C ) and Cdc42 (Fig. 4D) . Interestingly, DLC2 stimulated not only GTP hydrolysis of
RhoA, but also of Cdc42 ( Fig. 4B and 4D ). However, DLC2 poorly activated the GTP hydrolysis of Rac1 if compared to n-chimerin (Fig. 4C) , a known stimulator of Rac1 (33).
DLC2 did not activate another small G-protein Ras (data not shown).
DLC2-GAP suppresses Ras signaling and Ras-induced cellular transformation.
A growing body of evidence has suggested that small GTPases of the Rho family are by guest on January 8, 2018
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It is noteworthy that some GAP proteins, such as neurofibromin 1 that has RasGAP activity, are well-known tumor suppressors (40) . The demonstration of the RhoGAP activity of DLC2 (Fig. 4) prompted us to investigate the influence of DLC2 in cell signaling. Specifically, we asked whether the expression of DLC2 would suppress Rasand Rho-mediated oncogenic signaling and cellular transformation. However, the fulllength DLC2 protein could not be stably overexpressed in cultured mammalian cells (data not shown) probably due to cytotoxicity. This observation is consistent with a previous finding that rat DLC1 cannot be stably overexpressed in adherent cells because it induces morphological changes and cell detachment (41) .
To resolve the above issue and to explore the significance of the RhoGAP activity of DLC2 to its cellular functions, we performed functional studies in cultured cells using a truncated form of DLC2, which contains the intact RhoGAP domain. This form of DLC2, designated DLC2-GAP, can be efficiently expressed both in E. coli (Fig. 5A ) and in cultured mammalian cells. DLC2-GAP exhibits GAP activity on Cdc42 (Fig. 5B) as potent as the DLC2 full-length protein (Fig. 4D ). First we wished to assess the influence of DLC-GAP on Ras signaling because Ras has been well documented for its oncogenic property (42) and because Ras induces cell transformation partly through the activation of RhoA and Cdc42 (19) (20) (21) (22) . SRE represents one effector of Ras (43) and is efficiently activated by RasV12, a dominant active mutant of Ras (Fig. 5C , compare column 2 to column 1). We observed that DLC2-GAP specifically repressed the RasV12-induced activation of SRE-dependent luciferase reporter activity (Fig. 5C , compare column 3 to column 2). This repression was absolutely dependent on the GAP activity since the R699A mutant of DLC2-GAP, which did not show any GAP activity (Fig. 5B) , did not influence the RasV12 activation of SRE (Fig. 5C , compare column 4 to columns 2 and 3).
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http://www.jbc.org/ Downloaded from 13 DLC2-GAP had GAP activity on Cdc42 (Fig. 5B ) and more mildly on Rac1 (data not shown), but it did not show appreciable GAP activity on Ras (Fig. 5D) (43) (44) (45) . Thus, the inhibitory effect of DLC2-GAP on RasV12-induced activation of SRE could be attributed at least in part to its GAP activity on Cdc42 and/or other members in the Ras superfamily of small GTP-binding proteins.
Rho GTPases are well known activators of the actin cytoskeleton (19) . In particular,
RhoA plays a pivotal role in cytoskeletal reorganization and the formation of actin stress fibers (19, 44) . As a functional RhoGAP protein, rat DLC1 has been shown to induce disassembly of stress fibers and the morphological rounding of various adherent cells (41) .
To assess the functional status of DLC2-GAP in the cell, we expressed HA-tagged DLC2-GAP in HeLa cells and co-stained for HA and α-actin (Fig. 6 ). DLC2-GAP was abundantly expressed without inducing notable cytotoxic effects ( .6% inhibition of stress fiber formation by DLC2-GAP). In sharp contrast, the expression of the RhoGAP-defective DLC2-GAP R699A mutant had no effect on stress fiber formation (Fig. 6 , panels 5 and 6, cells highlighted by arrow). This GAP-dependent inhibition of Rho-mediated cytoskeletal reorganization by DLC2-GAP suggests that DLC2 might function as a RhoGAP in vivo.
14 Next we asked whether DLC2-GAP suppressed Ras-induced cellular transformation.
NIH3T3 cells were induced by RasV12 to form foci (Fig. 7B , compare column 2 to column 1), which is a characteristic property of transformed cells. When DLC2-GAP was co-transfected with RasV12, significantly less number of foci was observed compared to the vector control or the DLC2-GAP R699A mutant that has lost the RhoGAP activity ( Fig. 7A and Fig. 7B , compare column 4 to columns 2 and 3). In contrast, the expression of DLC2-GAP did not affect the formation of transformed foci induced by v-Jun (Fig. 7B , columns 5 and 6), a viral oncoprotein recovered from avian sarcoma virus 17 (30) . Our interpretation to the specific suppression of Ras-induced transformation of NIH3T3 cells is that DLC2-GAP acts through inactivating the RhoA and/or Cdc42 activity.
DISCUSSION
This study has established the growth suppressor function of DLC2 and the underexpression of DLC2 in human HCC tissues. We have shown that DLC2 at chromosome 13q12.3 ( Fig. 1) encodes a novel RhoGAP protein (Fig. 3) exhibiting specific GAP activity on RhoA and Cdc42 (Fig. 4) and is underexpressed in HCC (Fig. 2) .
In addition, DLC2 suppresses Ras activation of SRE (Fig. 5) , inhibits Rho-mediated cytoskeletal reorganization (Fig. 6) , and counteracts Ras-mediated cellular transformation in a GAP-dependent manner (Fig. 7) . DLC2 contains multiple functional domains, including SAM, RhoGAP and START, which may be important for its regulation. Little information is available for the function of START domain apart from that it can bind lipids and target proteins to membrane (38) .
Although the exact role of this domain in the regulation of DLC2 protein remains to be elucidated, it is tempting to speculate that the START domain is responsible for the recruitment of DLC2 to the membrane, where the substrates for its GAP activity are localized. Moreover, binding of lipid(s) to START may provide a mechanism to regulate the GAP activity of DLC2, analogous to the enhancement of GAP activity in n-chimerin through phospholipid binding to a protein kinase C-like domain (46) . DLC2 can stimulate the GTP hydrolysis of small GTPases RhoA and Cdc42 (Fig. 4, B and D). The full-length DLC2 protein also exhibits relatively low GAP activity on Rac1 (Fig. 4C) . We noted that the truncated DLC2-GAP protein has a moderate GAP activity on Rac1 but it poorly stimulates the GTP hydrolysis of RhoA in our assay (data not shown). We hypothesized that this discordance might due to conformational change of the recombinant DLC2-GAP protein possibly induced during the process of purification.
Nevertheless, our findings that the expression of DLC2-GAP in cells has an impact on SRE activation (Fig. 5C ), cytoskeletal reorganization ( Fig. 6 ) and transformation ( Fig. 7) consistently support the notion that DLC2-GAP and DLC2 function as RhoGAP in vivo.
It is generally accepted that Rho family proteins are involved in cell transformation; the molecular events for this process are however not well defined. The dissection of the signaling pathway is hampered by the cross talk between the Rho family members and by the limited information available for the downstream effectors. For example, the most common effector for Rac and Cdc42 is p21-activating kinase (PAK) 1, which does not induce transformation. However, a recently identified group II PAK family member, called PAK4, is able to induce transformation and is overexpressed in a large number of tumor cell lines (47) . Interestingly, PAK4 is more preferentially activated by Cdc42 (48) .
We noted that DLC2 selectively activated the GTP hydrolysis of Cdc42 (Fig. 4 and Fig.   5 ). This raised the possibility that PAK4 is a direct target for DLC2 signaling. Further experiments are undergoing to test this hypothesis.
Interactions between SAM domains are known to mediate homo-and heterooligomerization of proteins (36, 37) . Notably, the oligomerization of SAM domain has recently been implicated in leukemogenesis and transcriptional repression (49) . In this context, it would be of interest to elucidate whether SAM domain in DLC2 would be used are shown. C, Northern blot analysis of DLC2 in human tissues. To normalize for differences in RNA loading, the same blot was also probed for β-actin after stripping the DLC2 signal. C, Consensus phylogenetic tree relating DLC2 to other GAP proteins. Phylogenies were inferred from protein sequences using parsimony. Bootstrap replication was performed and the majority rule consensus tree was generated from 100 replicates. Numbers are by guest on January 8, 2018
